眼内激光光凝术在视网膜血管性疾病的玻璃体手术中的应用  

Application of Endolaser in Vitrectomy for Retinal Vascular Disease

作　　者：臧晶[1] 周斌兵[1] 鲍炯琳[1] 朱宇东[1] 林文雄[1] 李青[1] 卞庆宁[1] 张少冲[2] 高汝龙[2] 何利蓉[1] 

机构地区：[1]广州铁路中心医院眼科,广州510080 [2]中山大学中山眼科中心眼科,广州510060

出　　处：《Eye Science》2003年第4期221-223,共3页眼科学报（英文版）

摘　　要：目的:探讨眼内激光在视网膜血管性疾病的玻璃体切除术中的应用及有效性。 方法:将眼内激光应用于24例(28只眼)视网膜血管性疾病的玻璃体手术中。眼内光凝的方式:全视网膜光凝21只眼;环形激光视网膜拦截并封闭视网膜裂孔2只眼:局限性光凝5只眼。 结果:术后随访1～24个月(平均9个月),3只眼术后再次视网膜出血,其余25只眼均视网膜平伏、裂孔封闭、视力不同程度提高,未再有玻璃体积血发生,治愈率达89.2％。 结论:眼内激光光凝是现代玻璃体手术中重要的辅助工具,是视网膜血管性疾病玻璃体切除手术中一个重要而有效的步骤。眼科学报 2003;19:221-223。Purpose:To discuss the usage and effectiveness of endolaser in vitrectomy for retinal vascular disease. Methods: Twenty-four cases (28 eyes) of vitreetolny for retinal vascular disease were treated with endolaser. The methods of endolaser: 21 eyes were treated with panretinal scatter therapy; 2 eyes with endolaser ring-intercepting around retinal and sealing retinal breaks; 5 eye with focal therapy. Results: After follow-up for 1-24 months(mean 9 months), retinal hemorrhage recurred in 3 eyes; the other 25 eyes, retinas were totally reattached, retinal breaks were sealed, and vision had considerable recovery, no hemorrhage. The ratio of recovery is up to 89.2%. Conclusions: Endolaser is an important adjuvant in vitreous operation nowadays and an effective procedure in vitrectomy for the cases of retinal hemorrhage. Eye Science 2003; 19:221-223.

关 键 词：眼内激光光凝术 视网膜血管性疾病 玻璃体手术 视网膜出血 玻璃体积血 

分 类 号：R779.63[医药卫生—眼科]